Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, Daniel Mukadi-Bamuleka, Aboubacar Soumah, Zephyrin Mossoko, Tansy Edwards, Darius Tetsa-Tata, Rockyath Makarimi, Oumar Toure, Grace Mambula, Hannah Brindle, Anton Camacho, Nicholas E. Connor, Pierre Mukadi, Chelsea McLean, Babajide Keshinro, Auguste Gaddah, Cynthia Robinson, Kerstin Luhn, Julie Foster, Chrissy h. Roberts, John Emery Johnson, Nathalie Imbault, Daniel G. Bausch, Rebecca F. Grais, Deborah Watson-Jones, Jean Jacques Muyembe-Tamfum
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-07-01
coleção:	Vaccines
Assuntos:	Ebola outbreak Democratic Republic of the Congo DRC vaccine immunogenicity
Acesso em linha:	https://www.mdpi.com/2076-393X/12/8/828
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!